Peregrine Pharmaceuticals (NASDAQ:PPHM)

CAPS Rating: 2 out of 5

A biopharmaceutical company with a portfolio of clinical stage and pre-clinical product candidates using monoclonal antibodies for the treatment of cancer and viral diseases.

Recs

0
Player Avatar usubanas (99.54) Submitted: 1/10/2013 12:18:20 PM : Underperform Start Price: $2.14 PPHM Score: +8.96

I don't trust this company

Featured Broker Partners


Advertisement